demplatin pegraglumer: Clinical Trials

6 trials of demplatin pegraglumer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated, 1 unknown. 4 Phase 1, 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1
Phase 24Completed 3, Unknown 1
Phase 31Completed 1

Follow demplatin pegraglumer: new trials by email Literature Review of demplatin pegraglumer trials Research Report on demplatin pegraglumer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
NC-6004, Pembrolizumab - SCCHN
Phase 2UnknownNanoCarrier Co., Ltd.1362019-07-012021-03-17
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NC-6004, Cetuximab, 5-FU - Carcinoma, Squamous Cell of Head and Neck
Phase 1 / Phase 2CompletedNanoCarrier Co., Ltd.12017-03-012019-04-29
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
NC-6004, Cetuximab, 5-FU - Head and Neck Neoplasms
Phase 1TerminatedOrient Europharma Co., Ltd.42016-06-012021-04-30
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NC-6004, Gemcitabine - Solid Tumors
Phase 1 / Phase 2CompletedNanoCarrier Co., Ltd.1192014-05-012025-01-22
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
NC-6004, Gemcitabine - Pancreatic Neoplasms
Phase 3CompletedOrient Europharma Co., Ltd.3102014-01-012020-04-15
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
Nanoplatin (NC-6004) and Gemcitabine - Locally Advanced and Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletedNanoCarrier Co., Ltd.402009-05-012014-01-09

Conditions studied

Pancreatic Neoplasms (2)  ·  Carcinoma, Squamous Cell (1)  ·  Head and Neck Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

NanoCarrier Co., Ltd. (4)  ·  Orient Europharma Co., Ltd. (2)

Countries

Taiwan (4)  ·  Bulgaria (2)  ·  Hungary (2)  ·  Poland (2)  ·  Romania (2)  ·  Singapore (2)  ·  United States (2)  ·  Croatia (1)  ·  Czechia (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Japan (1)  ·  Malaysia (1)  ·  Philippines (1)  ·  Russia (1)

Top investigators

Atsushi Osada (1)  ·  Atsushi Osada, Study Director (1)  ·  Joao da Silva, MD (1)  ·  Li-Tzong Chen, M.D., Ph. D. (1)  ·  Ruey-Long Hong, MD PhD (1)  ·  Wu-Chou Su, MD (1)